Information  X 
Enter a valid email address

PureTech Health PLC (PRTC)

  Print      Mail a friend

Wednesday 02 January, 2019

PureTech Health PLC

Total Voting Rights

RNS Number : 8677L
PureTech Health PLC
02 January 2019
 

2 January 2019

 

PureTech Health plc

Total Voting Rights and Share Capital - Month End Disclosure

Pursuant to DTR 5.6.1 of the Disclosure Guidance and Transparency Rules:

As at 31 December 2018 the issued share capital of PureTech Health plc comprised 282,493,867 Ordinary shares of one pence each.  There were no shares held in treasury.

The total number of voting rights in PureTech Health plc is therefore 282,493,867.

This information may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules. 

 

About PureTech Health

PureTech Health (LSE: PRTC) is an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis. The Company has developed deep insights into the connection between the individual components of these systems and the resulting role in many chronic diseases, which have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases.

 

PureTech Health is advancing a rich pipeline of innovative therapies across two divisions: the Affiliates division and the Internal division. Its Affiliates division includes two product candidates that have been filed with the US Food and Drug Administration (FDA) for review and several other novel clinical and pre-clinical programmes. These affiliates are developing ground-breaking platforms and therapeutic candidates in collaboration with some of the world's leading experts.

 

PureTech's Internal division is advancing a pipeline fuelled by recent discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. These programmes leverage the transport and biodistribution of various immune system components for the targeted treatment of diseases with major unmet needs, including cancers, autoimmune diseases, and neuroimmune disorders.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Contact:


PureTech Health

FTI Consulting


Allison Mead Talbot

+1 617 651 3156

[email protected]

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVRUGUQAGUPBGBG

a d v e r t i s e m e n t